Cardiovascular Systems Revenue 2006-2019 | CSII

Cardiovascular Systems revenue from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Cardiovascular Systems Annual Revenue
(Millions of US $)
2019 $248
2018 $217
2017 $205
2016 $178
2015 $182
2014 $137
2013 $104
2012 $82
2011 $79
2010 $65
2009 $56
2008 $
2008 $22
2007 $59
2007 $
2006 $16
2006 $
2005 $0
2005 $
Cardiovascular Systems Quarterly Revenue
(Millions of US $)
Q4 2019 $68
Q3 2019 $63
Q2 2018 $60
Q1 2018 $56
Q4 2018 $59
Q3 2018 $56
Q2 2017 $53
Q1 2017 $50
Q4 2017 $53
Q3 2017 $52
Q2 2016 $50
Q1 2016 $50
Q4 2016 $48
Q3 2016 $44
Q2 2015 $41
Q1 2015 $44
Q4 2015 $48
Q3 2015 $47
Q2 2014 $45
Q1 2014 $41
Q4 2014 $40
Q3 2014 $35
Q2 2013 $32
Q1 2013 $30
Q4 2013 $29
Q3 2013 $26
Q2 2012 $25
Q1 2012 $23
Q4 2012 $23
Q3 2012 $21
Q2 2011 $20
Q1 2011 $19
Q4 2011 $22
Q3 2011 $20
Q2 2010 $19
Q1 2010 $18
Q4 2010 $18
Q3 2010 $17
Q2 2009 $15
Q1 2009 $15
Q4 2009 $16
Q3 2009 $15
Q2 2008
Q1 2008 $12
Q4 2008
Q3 2008 $8
Q2 2007
Q1 2007
Q4 2007 $56
Q3 2007 $3
Q2 2006
Q1 2006 $4
Q4 2006 $4
Q3 2006 $3
Q2 2005
Q1 2005 $0
Q4 2005
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $1.682B $0.248B
Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360? Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease; and a range of plaque types, including calcified vessel lesions. The Diamondback 360? removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company refined its `orbital` technology to address the growing market need of providing a safer more effective atherectomy device.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $149.840B 28.17
Medtronic (MDT) Ireland $137.817B 19.69
Stryker (SYK) United States $81.180B 28.07
Boston Scientific (BSX) United States $58.714B 28.48
Baxter (BAX) United States $44.403B 26.93
EssilorLuxottica Societe Anonyme (ESLOY) France $30.829B 0.00
Zimmer Biomet Holdings (ZBH) United States $28.130B 18.00
Coloplast (CLPBY) Denmark $26.395B 42.14
Lonza Group Ag (LZAGY) Switzerland $26.038B 0.00
Terumo (TRUMY) Japan $23.788B 27.35
Smith & Nephew SNATS (SNN) United Kingdom $20.267B 0.00
ResMed (RMD) United States $19.315B 36.83
Sunny Optical Technology (SNPTF) China $13.689B 0.00
Bio-Rad Laboratories (BIO) United States $9.759B 52.32
Canopy Growth (CGC) Canada $9.745B 0.00
Insulet (PODD) United States $9.055B 536.57
William Demant Holdings (WILYY) Denmark $7.136B 0.00
Haemonetics (HAE) United States $7.033B 53.07
Hill-Rom Holdings (HRC) United States $7.032B 20.97
Perrigo (PRGO) Ireland $6.283B 11.57
Aurora Cannabis (ACB) Canada $6.094B 59.90
GN STORE NORD (GNNDY) Denmark $5.897B 30.11
GW Pharmaceuticals (GWPH) United Kingdom $4.651B 0.00
Shandong Weigao Medical Polymer (SHWGF) China $4.296B 0.00
Neogen (NEOG) United States $3.710B 61.70
ICU Medical (ICUI) United States $3.430B 22.25
NuVasive (NUVA) United States $3.316B 26.44
Hutchison China MediTech (HCM) China $2.737B 0.00
Quidel (QDEL) United States $2.552B 25.34
Agios Pharmaceuticals (AGIO) United States $2.491B 0.00
National Vision Holdings (EYE) United States $2.177B 46.98
Aphria (APHA) $1.551B 0.00
Phibro Animal Health (PAHC) United States $1.263B 18.92
AtriCure (ATRC) United States $1.060B 0.00
VAREX IMAGING (VREX) United States $1.018B 23.45
NanoString Technologies (NSTG) United States $0.977B 0.00
Omeros (OMER) United States $0.967B 0.00
PetIQ (PETQ) United States $0.908B 21.44
Lantheus Holdings (LNTH) United States $0.897B 23.57
Eagle Pharmaceuticals (EGRX) United States $0.794B 20.23
Cerus (CERS) United States $0.769B 0.00
MacroGenics (MGNX) United States $0.737B 0.00
Quanterix (QTRX) United States $0.702B 0.00
TG Therapeutics (TGTX) United States $0.648B 0.00
LeMaitre Vascular (LMAT) United States $0.626B 37.08
Surmodics (SRDX) United States $0.601B 114.26
OraSure Technologies (OSUR) United States $0.446B 20.63
Meridian Bioscience (VIVO) United States $0.432B 13.48
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.423B 0.00
BioLife Solutions (BLFS) United States $0.376B 123.63
United Health Products (UEEC) United States $0.350B 0.00
Utah Medical Products (UTMD) United States $0.349B 25.56
Zynex (ZYXI) United States $0.345B 36.62
Owens & Minor (OMI) United States $0.306B 9.17
Bovie Medical (APYX) United States $0.251B 0.00
Vapotherm (VAPO) United States $0.244B 0.00
Cytosorbents (CTSO) United States $0.155B 0.00
Chimerix (CMRX) United States $0.153B 0.00
Fonar (FONR) United States $0.152B 8.01
Rockwell Medical (RMTI) United States $0.152B 0.00
Female Health (VERU) United States $0.123B 0.00
Chembio Diagnostics (CEMI) United States $0.097B 0.00
United-Guardian (UG) United States $0.087B 20.65
Oramed Pharmaceuticals (ORMP) United States $0.057B 0.00
Surface Oncology (SURF) United States $0.055B 0.00
Nephros (NEPH) United States $0.054B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
Trinity Biotech (TRIB) Ireland $0.041B 14.17
Senestech (SNES) United States $0.039B 0.00
Valeritas Holdings (VLRX) United States $0.013B 0.00
Capricor Therapeutics (CAPR) United States $0.011B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.010B 0.00
GUARDION HEALTH (GHSI) United States $0.006B 0.00
Akers Biosciences Inc (AKER) United States $0.005B 0.00
NeuroMetrix (NURO) United States $0.003B 0.00